Adverse Reactions to Protamine Sulfate used for Heparin Neutralization in a Dog Receiving a Blood Transfusion

다국어 초록 (Multilingual Abstract)

A 14-year-old castrated male ShihTzu diagnosed with chronic kidney disease (CKD) 6 months prior was referred to our clinic. The patient had been experiencing symptoms such as vomiting, poor appetite and hind limbs weakness. Hematology tests showed that he had a non-regenerative anemia. With aggressive treatment, the patient’s state had gotten worse. He showed ragged breath, vomiting blood and loss of consciousness temporarily. Hematocritmaintained low level. Gastric hemorrhage was strongly suspected by hematemesis. Whole blood transfusion was performed and heparin was used as an anticoagulant. Prior to transfusion, the blood cross matching between donor and patient was performed and the result was compatible. After the transfusion was stabilized, 1 mg of protamine sulfate for each 100 units of heparin was prepared and given intravenously over 3 minutes to reverse the effects of heparin. Immediately after protamine injection, the patient conducted severe anaphylactic shock. Protamine sulfate is used to reverse the anticoagulant action of heparin in dogs and humans. The adverse reaction of protamine sulfate range from mild reaction to fetal cardiac arrest. When sing protamine sulfate as heparin neutralization, it can lead to the death of a patient cause of anaphylactic shock. For this reason, the protamine sulfate should be injected slowly with antihistamine and the clinician should carefully monitor patients.

참고문헌 (Reference)

1 Carr J, "The heparin-protamine interaction : a review" 40 : 659-, 1999

2 Adkins JR, "Sodium heparin neutralization and the anticoagulant effects of protamine sulfate" 94 : 175-177, 1967

3 Ransdell HT, "Renal toxicity of polybrene (hexadimethrine bromide)" 5 : 195-199, 1965

4 Frater R, "Protamine-induced circulatory changes" 87 : 687-692, 1984

5 Horrow JC, "Protamine : a review of its toxicity" 64 : 348-361, 1985

6 Kambam J, "Prophylactic administration of histamine 1 and histamine 2 receptor blockers in the prevention of protaminerelated haemodynamic effects" 37 : 420-422, 1990

7 Mayumi H, "Pretreatment with H2blocker famotidine to ameliorate protamine-induced hypotension in open-heart surgery" 33 : 738-745, 1992

8 Eika C, "On the mechanism of platelet aggregation induced by heparin, protamine and polybrene" 9 : 248-257, 1972

9 Fadali MA, "Mechanism responsible for the cardiovascular depressant effect of protamine sulfate" 180 : 232-235, 1974

10 Yoo KY, "Mechanism of the Hypotension Produced Protamine Sulfate in Dogs" 34 : 27-38, 1998

11 Chang L-C, "Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote(III) : preliminary in vivo evaluation of efficacy and toxicity using a canine model" 3 : 24-31, 2001

12 Li J, "Heparin and protamine stimulate the production of nitric oxide" 37 : 445-452, 1996

13 Wakefield TW, "Decreased oxygen consumption as a toxic manifestation of protamine sulfate reversal of heparin anticoagulation" 9 : 772-777, 1989

14 Goldman BS, "Cardiovascular effects of protamine sulfate" 7 : 459-471, 1969

15 Ching KS, "Cardiopulmonary effects of protamine in man" 53 : S116-, 1980

16 Wakefield T, "Attenuation of hemodynamic and hematologic effects of heparin-protamine sulfate interaction after aortic reconstruction in a canine model" 100 : 45-51, 1986

17 Porsche R, "Allergy to protamine sulfate" 28 : 418-428, 1999

18 Jaques LB, "A study of the toxicity of the protamine, salmine" 4 : 135-144, 1949